• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

CAPMATINIB Drug Record

  • Summary
  • Interactions
  • Claims
  • CAPMATINIB chembl:CHEMBL3188267 Antineoplastic

    Alternate Names:

    INCB-28060 FREE BASE
    INCB-28060
    NYP-INC280-NX
    INC-280
    NVP-INC280
    CAPMATINIB
    NVP-INC280-NX
    INC280
    TABRECTA
    INCB28060
    chemidplus:1029712-80-8
    pubchem.compound:25145656
    drugbank:11791
    chembl:CHEMBL3188267

    Drug Info:

    Drug Class Kinase Inhibitors
    Pharmaceutical Developer Novartis
    Source Reported Drug Name(s) INC280
    Drug Class MET Inhibitor
    (6 More Sources)

    Publications:

    Yao et al., 2017, Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS., Nature
    Frampton et al., 2015, Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors., Cancer Discov
    Li et al., 2017, Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non-Small Cell Lung Cancer., Clin. Cancer Res.
    Choi et al., 2004, Molecular mechanisms of heptaplatin effective against cisplatin-resistant cancer cell lines: less involvement of metallothionein., Cancer Cell Int.
    Bahcall et al., 2016, Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer., Cancer Discov
    Engstrom et al., 2017, Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-Mediated Resistance to Type I MET Inhibitors in Nonclinical Models., Clin. Cancer Res.
    Wolf J et al., 2020, Capmatinib in <i>MET</i> Exon 14-Mutated or <i>MET</i>-Amplified Non-Small-Cell Lung Cancer., N Engl J Med
  • CAPMATINIB   MET

    Interaction Score: 2.36

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Reported Cancer Type Melanoma
    Indication/Tumor Type lung large cell carcinoma
    Response Type sensitive

    PMIDs:
    28396313 15494073 28783719 27694386 28765324 25971938 32877583


    Sources:
    TALC MyCancerGenome JAX-CKB ChemblInteractions COSMIC CIViC CancerCommons TTD OncoKB

  • CAPMATINIB   BRAF

    Interaction Score: 0.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type collecting duct carcinoma
    Response Type sensitive
    Approval Status Preclinical - Pdx

    PMIDs:
    28783719


    Sources:
    JAX-CKB

  • CAPMATINIB   EGFR

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type collecting duct carcinoma
    Approval Status Preclinical - Pdx
    combination therapy INC280 + Trametinib

    PMIDs:
    28783719


    Sources:
    JAX-CKB

  • CAPMATINIB   TP53

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Clinical Study
    Response Type sensitive

    PMIDs:
    25971938


    Sources:
    JAX-CKB

  • MyCancerGenome: INCB028060

    • Version: 20-Jun-2017

    Alternate Names:
    INCB028060 Development Name
    INC280 Development Name

    Drug Info:
    Drug Class Kinase Inhibitors

    Publications:

  • CancerCommons: INC280

    • Version: 25-July-2013

    Alternate Names:
    INC280 Drug Trade Name
    INC280 Drug Development Name

    Drug Info:
    Drug Class MET Inhibitor
    Source Reported Drug Name(s) INC280
    Pharmaceutical Developer Novartis

    Publications:

  • JAX-CKB: INC280

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Yao et al., 2017, Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS., Nature
    Bahcall et al., 2016, Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer., Cancer Discov
    Frampton et al., 2015, Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors., Cancer Discov

  • CIViC: CAPMATINIB

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Frampton et al., 2015, Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors., Cancer Discov
    Wolf J et al., 2020, Capmatinib in <i>MET</i> Exon 14-Mutated or <i>MET</i>-Amplified Non-Small-Cell Lung Cancer., N Engl J Med

  • TTD: INCB28060

    • Version: 2020.06.01

    Alternate Names:
    D07OJZ TTD Drug ID

    Drug Info:

    Publications:

  • TALC: INCB28060

    • Version: 12-May-2016

    Alternate Names:
    INCB28060 Primary Drug Name
    INCB28060 Drug Synonym

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL3188267

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL3188267

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

  • OncoKB: Capmatinib

    • Version: 23-July-2020

    Alternate Names:

    Drug Info:

    Publications:

  • COSMIC: Capmatinib

    • Version: 4-Sep-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21